PDCD1 and metastatic melanoma: The anti-PD-1 Ab significantly prolongs survival in patients with metastatic melanoma, and its administration in combination with local [4–8] or systemic therapy (e.g., ipilimumab, epacadostat) [2, 9] may also lead to improved outcomes.